XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and Licensing Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2020 and 2019.
| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
ZIOPHARM Oncology, Inc. | $ | — |  |  | $ | 533 |  |  | $ | 100 |  |  | $ | 1,699 |
Oragenics, Inc. | 32 |  |  | 181 |  |  | 230 |  |  | 382 |
Intrexon Energy Partners, LLC | — |  |  | 796 |  |  | — |  |  | 1,773 |
Intrexon Energy Partners II, LLC | — |  |  | 420 |  |  | — |  |  | 924 |
Fibrocell Science, Inc. | 4,210 |  |  | 2,462 |  |  | 14,573 |  |  | 2,845 |
Harvest start-up entities (1) | — |  |  | 2,039 |  |  | — |  |  | 4,762 |
Other | 73 |  |  | 19 |  |  | 133 |  |  | 36 |
Total | $ | 4,315 |  |  | $ | 6,450 |  |  | $ | 15,036 |  |  | $ | 12,421 |
(1)For the three and six months ended June 30, 2019, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.
Summary of Deferred Revenue | Deferred revenue consisted of the following:
| June 30, 2020 |  | December 31, 2019
Collaboration and licensing agreements | $ | 36,152 |  |  | $ | 50,593 |
Prepaid product and service revenues | 3,033 |  |  | 2,805 |
Other | 265 |  |  | 435 |
Total | $ | 39,450 |  |  | $ | 53,833 |
Current portion of deferred revenue | $ | 6,592 |  |  | $ | 5,697 |
Long-term portion of deferred revenue | 32,858 |  |  | 48,136 |
Total | $ | 39,450 |  |  | $ | 53,833 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of June 30, 2020 and December 31, 2019, as well as the estimated remaining performance period as of June 30, 2020.
| Average Remaining Performance Period (Years) |  | June 30, 2020 |  | December 31, 2019
Oragenics, Inc. | 3.9 |  | $ | 2,823 |  |  | $ | 2,864 |
Intrexon Energy Partners, LLC | 3.7 |  | 8,362 |  |  | 8,362 |
Intrexon Energy Partners II, LLC | 4.4 |  | 12,843 |  |  | 12,843 |
Fibrocell Science, Inc. | 1.0 |  | 3,308 |  |  | 17,697 |
Harvest start-up entities (1) | 4.7 |  | 6,993 |  |  | 6,993 |
Other | 2.3 |  | 1,823 |  |  | 1,834 |
Total |  |  | $ | 36,152 |  |  | $ | 50,593 |
(1)As of June 30, 2020 and December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | pgen_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | pgen_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration